Physicochemical Properties
| Molecular Formula | C27H25CLN2O3 |
| Molecular Weight | 460.95200 |
| Exact Mass | 460.155 |
| CAS # | 937807-66-4 |
| PubChem CID | 16112820 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 669.0±55.0 °C at 760 mmHg |
| Flash Point | 358.4±31.5 °C |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.613 |
| LogP | 6.42 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 33 |
| Complexity | 608 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | FEEOFPAEDSMOTO-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C27H21ClN2O3/c1-31-21-10-6-17(7-11-21)25-26(18-8-12-22(32-2)13-9-18)30-27(29-25)24-15-14-23(33-24)19-4-3-5-20(28)16-19/h3-16H,1-2H3,(H,29,30) |
| Chemical Name | 2-[5-(3-chlorophenyl)furan-2-yl]-4,5-bis(4-methoxyphenyl)-1H-imidazole |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | P19 cells treated with neurodazine (5 μM; 1–10 days) exhibit markers unique to neurons [1]. Neurodazine specifically prevents P19 cells from differentiating into astrocytes [1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: P19 Cell Tested Concentrations: 5 μM Incubation Duration: 1-10 days Experimental Results: Induced expression of neuron-specific markers. |
| References |
[1]. Imidazole-based small molecules that promote neurogenesis in pluripotent cells. Angew Chem Int Ed Engl. 2014 Aug 25;53(35):9271-4. [2]. Synthetic small molecules that induce neuronal differentiation in neuroblastoma and fibroblast cells. Mol Biosyst. 2015 Oct;11(10):2727-37. |
| Additional Infomation | 2-[5-(3-chlorophenyl)-2-furanyl]-4,5-bis(4-methoxyphenyl)-1H-imidazole is a member of imidazoles. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~218.86 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.47 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.47 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1694 mL | 10.8472 mL | 21.6943 mL | |
| 5 mM | 0.4339 mL | 2.1694 mL | 4.3389 mL | |
| 10 mM | 0.2169 mL | 1.0847 mL | 2.1694 mL |